Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Latent Cancer Prostate
Interventions
DRUG

Ga-68 PSMA ligand

"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."

Trial Locations (1)

333

Chang Gung Memorial Hospital ,Linkou, Taoyuan

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03207139 - Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer | Biotech Hunter | Biotech Hunter